Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab
Status:
Unknown status
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase I/II study of Intravitreally administered 0.3mg ranibizumab in
subjects with persistent Diabetic Macular Edema (DME) after recent and frequent bevacizumab
(at least 2 bevacizumab intravitreal injections within 2 months prior to enrollment and at
least 6 bevacizumab injections within 9 months of enrollment).